Startup Due diligence

Why due diligence matters in life sciences

In regulated sectors, risk often hides in places that are easy to miss without specialized expertise.

A company may present a promising product, strong science, and a compelling commercial story. But the real questions are often more operational and regulatory:

• Is the development pathway realistic?
• Is the product positioned correctly from a regulatory perspective?
• Are quality systems mature enough for the next stage?
• Is the documentation complete, current, and internally consistent?
• Are manufacturing activities controlled and scalable?
• Are there unresolved compliance, validation, or data integrity issues?
• How much remediation will actually be needed after investment or acquisition?

These questions matter because regulatory and quality weaknesses can directly affect timelines, valuation, transaction structure, and future execution. Public analyses of FDA warning letters have repeatedly shown that common underlying problems include process validation deficiencies, documentation failures, and quality control weaknesses. In Europe, inspection and compliance oversight similarly focuses on whether companies meet GMP, GCP, GLP, and related regulatory principles.

What ADRES evaluates

ADRES conducts due diligence evaluations with a practical, multidisciplinary lens. Depending on the deal type and company stage, we assess issues such as:

Regulatory status and strategy

We review the current regulatory position of the company, product, or portfolio and assess whether the proposed pathway is credible, complete, and aligned with target markets. This can include development stage review, classification questions, submission strategy, agency interactions, approval pathway logic, and the realism of future milestones.

Quality systems and compliance maturity

We assess the maturity of the quality management system and the extent to which the organization is operating in a controlled, inspection-ready way for its stage. This may include quality procedures, deviation handling, CAPA, change control, training systems, supplier oversight, and management responsibility.

CMC and manufacturing readiness

We evaluate manufacturing strategy, technical control, process understanding, analytical readiness, technology transfer exposure, vendor oversight, and the overall readiness of the CMC package for future development, scale-up, filing, or commercialization.

Documentation and data reliability

In life sciences, decisions are only as strong as the underlying records. We review the completeness, consistency, traceability, and usability of the documentation available, including whether critical claims are actually supported by data and whether the documentation would stand up in a regulatory, investor, or partner review process.

Operational capability

A company may have outsourced much of its development, but that does not remove execution risk. We assess whether the company is effectively managing CROs, CDMOs, consultants, laboratories, and other external partners, and whether internal oversight is strong enough to keep the program on track.

Risk exposure and remediation burden

We identify the issues that are most likely to create downstream cost, delay, or execution failure. Just as important, we help estimate the likely remediation burden so investors or acquirers understand not only what is wrong, but what it may take to fix.

Who this service is for

Our due diligence support is relevant for:

• investors evaluating early-stage or growth-stage life sciences companies
• buyers assessing acquisition targets, product lines, or platforms
• companies preparing for licensing or strategic partnership discussions
• startups preparing for investor review and wanting to identify weaknesses in advance
• executive teams that want an independent assessment before a major transaction or milestone

How ADRES works

Every diligence project starts with the business question.

Sometimes the goal is to support an investor deciding whether to move forward. Sometimes it is to assess a product before acquisition. Sometimes it is to help a startup prepare for investor scrutiny by identifying weaknesses before the market sees them.

We tailor the scope accordingly, but our approach usually includes:

• review of available documentation and background materials
• focused evaluation across RA, QA, CMC, and development functions
• identification of critical gaps, inconsistencies, and red flags
• prioritization of issues by severity and likely business impact
• practical interpretation of findings for decision makers
• optional support for remediation planning after the evaluation

What clients gain from a due diligence evaluation

A strong diligence process should do more than produce observations. It should improve the quality of the decision.

ADRES helps clients:

• uncover hidden regulatory and compliance risks
• understand whether the development plan is realistic
• assess the maturity of the company beyond the pitch deck
• estimate remediation effort before committing resources
• strengthen negotiation position in deals and partnerships
• prepare more effectively for investment, acquisition, or strategic review

Due Diligence Evaluation	Early Stage	Pre-clinical	Clinical	Registration	Market
Due diligence evaluation Evaluating available information about a company status to reach an informed judgment as to its value for a specific purpose

Why ADRES

ADRES brings together regulatory affairs, quality assurance, CMC, and broader development thinking in one diligence process. That matters because in life sciences, risks rarely sit in one department alone.

A weak filing strategy can be linked to incomplete CMC planning. A quality issue can reflect poor vendor control. A strong product story may not survive detailed review of the documentation. We connect those dots and present the findings in a way that is technically sound and commercially useful.

Typical due diligence questions we help answer

• Is the company truly ready for the next development stage?
• Are the regulatory assumptions credible?
• Are there hidden GMP, GCP, or quality system risks?
• Is the manufacturing strategy viable?
• Are the documents consistent with the story being presented?
• How much remediation is likely after closing or investment?
• What are the highest-risk issues that could affect valuation or timeline?

Need due diligence before investment, acquisition, or partnership?
ADRES identifies hidden risks, exposes gaps, and equips you with the clarity to make fast, confident decisions. Contact us today to discuss your project